



Analyses of longitudinal health data

Murray D Smith

Community and Health Research Unit (CaHRU) University of Lincoln March 17, 2021

Background

 Panel data (aka longitudinal data, repeated measures) are repeated observations on the same cross-section

		Cups of tea								
Name	Morning	Noon	Night							
Murray	X	у	Ζ							
Merilyn	p	q	r							





	(Dog owner			
Name	Week	Morning	Noon	Night	
Murray	Monday	X	у	Ζ	Yes
Murray	Next Monday	а	b	С	Yes
Merilyn	Monday	p	q	r	No
Merilyn	Next Monday	S	t	u	No

	Cup	s on Mor	nday	Cups o	on Monda	Dog owner	
Name	am	noon	pm	am	noon	pm	
Murray	x	у	Z	а	b	С	Yes
Merilyn	р	q	r	S	t	u	No





Panel data $\{Y_{it}\}$

where index i = 1, ..., N runs across individuals

and index t = 1, ..., T runs across time periods

with potential to have a grand total of up to NT observations recorded on variable Y





Magic and Magic2



- Functional constipation in children is common with pooled prevalence of 14% for ages 0-18 years
- Management is challenging and based on reported symptoms
- An objective measure of whole gut transit time (WGTT) could assist in directing therapy
- Under standard care, measuring WGTT involves using X-ray radiopaque markers. Main drawbacks:

 (i) it provides an ionising radiation dose, and
 (ii) it is unable to accurately define the colon anatomy
- Magnetic resonance imaging (MRI) can offer a better alternative





The mini-capsules (TransiCap[®], JEB Technologies Ltd) are classed as an inertmarker ingestible medical device (European Union Class IIa). They enter the body via the oral cavity and travel inside the GI tract where they can be located using MRI



Child swallows 24 capsules per day on 3 consecutive days (day 1, 2, 3)

MRI scans taken on day 4 and day 7


MHRA asked for information:

- (i) How long will it take until all capsules are expelled from the body?
- (ii) Does ingestion of capsules have an adverse effect on health?





Time to complete expulsion



Magic data on n=16 constipated; mean predicted clearance 8.3 days 9 14

Magic data on n=19 healthy controls; mean predicted clearance 7.5 days

(58	23	38	45	19	25	36	16	43	15	23	19	48	18	38	16	43	46	26
3	0	16	17	10	0	0	3	0	0	0	7	9	0	0	0	3	12	0





 $EQVAS_{it}$ = CYP self-rated health on day t

(score between 0 (worst) and 100 (best); baseline is day 0)

 $Ingest24_{it}$ = 1 if 24 mini-capsules ingested on day t, 0 otherwise

 $Numcaps_{it}$ = piecewise linear interpolation for the number of mini-caps in body on day t

Model the baseline adjusted change in self-reported health using individual fixed effects

$\{EQVAS_{it} - EQVAS_{i0}\}$	Healthy Controls (N=15, NT=115)	Constipated (N=11, NT=115)
Ingest24	-2.10 (se=1.12; p=0.03)	3.21 (se=1.94; p=0.95)
Numcaps	-0.08 (se=0.05; p=0.04)	-0.10 (se=0.05; p=0.09)

Health adversely affected in the controls but probable placebo effect in the target group





British Lung Foundation



Economic Evaluation of Sport England's Active Steps

- Active Steps is remote health coaching BLF Helpline, website, social media platforms – designed to engage inactive people living with chronic lung conditions to become and stay physically active over a 12 month period
- Independent, parallel standard care trial assigned a similar protocol served as the control arm
- Data collections scheduled at baseline, 3, 6 and 12 months create a set of panel data





- For the economic evaluation the standard measures were to be gathered:
 - EuroQoL EQ-5D health-related quality of life
 - Bespoke NHS resource use questionnaire with 3-month recall when used at baseline, 3- and 6-month follow-ups and 6-month recall when used at the 12month follow-up
 - Baselines
 - Active Steps: 177 taken between 4 Feb 2019 and 19 Mar 2020
 - Control: 77 taken between 26 Jul 2019 and 27 Dec 2019
- ... and then COVID-19 and social distancing and furlough and lockdowns and extreme clinical vulnerabilities and shielding happened







- Economic dropouts 36% in Active Steps (only 4% in Control)
- 5 known deaths
- Many data follow-ups missing
- Many data follow-ups mistimed
- Summary an abundance of protocol violations

- Example: Active Steps baseline 4 Feb 2019 (1st recruit)
 - Follow-up 1: scheduled 4 May 2019, conducted 10 May 2019
 - Follow-up 2: scheduled 4 Aug 2019, conducted 12 Aug 2019
 - Follow-up 3: scheduled 4 Feb 2020, conducted 29 Apr 2020 (85 days late)









Summary of deterministic economic results: MRC Dyspnoea 3-5 subgroup

	Aggregate cost (£)	Recall years	Total cost (£ pa)	Total QALY	Life years	QALY (QALY pa)	ICER (£/QALY)				
MRC Dyspnoea 3-5											
AS (n=63)	67,940	30.1	2,254	20.7	37.8	0.547					
IC (n=51)	84,671	38.5	2,200	20.9	39.9	0.523	2,237				
difference			53			0.024					
MRC Dyspnoea 3-5 ignore protocol violations											
AS (n=63)	69,444	31.0	2,240	19.9	36.0	0.552					
IC (n=51)	90,450	36.0	2,141	22.3	42.75	0.522	3,294				
difference			99			0.030					

Note: from baselines, the annualised total cost COVID-19 unaffected averages £3,755







Green Whistle




- Methoxyflurane (Penthrox[®]; Galen Ltd) is a volatile fluorinated hydrocarbon anaesthetic with analgesic properties in sub-anaesthetic doses
- European licence for emergency relief of moderate to severe pain in conscious adults with trauma pain
- Limited evidence of benefits and costs in the prehospital setting
- Pain score (0-10) and the time when taken are the two key pieces of data





Pain scores



#Scores	Freq					
2	432					
3	330 (76.4%)					
4	59 (13.7%)					
5	10 (2.3%)					
6	3 (0.7%)					
7	1 (0.2%)					

Name	Score 1	Time 1	Score 2	Time 2	Score 3	Time 3	
PID 001	S 11	T 11	S 12	T 12	S 13	Т13	
PID 002	S 21	T 21	S 22	T 22	S 23	Т23	
PID 003	S 31	Тз1	S 32	Тз2	S 33	Тзз	





Panel data: Pain scores by patient and number taken

 $\{S_{ij}\} \begin{array}{l} S_{ij} \text{ denotes the pain score reported by patient } i = 1, \dots, N \text{ taken in sequence} \\ j = 0, 1, \dots, T_i \text{ over time, where } S_{i0} \text{ denotes the baseline score and } T_i \text{ is the total} \\ \text{number of scores taken on patient } i \text{ while under analgesia.} \end{array}$

 $\{t_{ij}\}$ The time (in minutes) at which the j^{th} pain score is taken on the i^{th} patient is denoted $t_{ij} \ge 0$, where baseline $t_{i0} = 0$.

Modelling approach:

Pain = f(time) diminishing at a decreasing rate under analgesia


$$S_{ij} = \beta_0 + \beta_1 t_{ij} + \beta_2 t_{ij}^2 + \cdots$$
 quadratic in time

expect $\beta_1 < 0$ and small $\beta_2 > 0$ speed of effect depends mainly on β_1





Predicted pain pathways: methoxyflurane (red), morphine IV (blue)









Thank you Contact: mdsmith@lincoln.ac.uk



